MetaVia Secures 39 Patents Until 2041, DA-1726 Achieves 9% Weight Loss
MetaVia secured 39 patents for its lead obesity drug DA-1726 in the U.S. and internationally, extending intellectual property protection through 2041. Recent Phase 1b data showed a 9% mean weight loss at the 48 mg dose, supporting potential market value and bolstering long-term exclusivity.
1. Patent Protection Extended Through 2041
MetaVia has secured 39 granted and pending patents on DA-1726 across the U.S. and key international markets, ensuring exclusive rights to its dual GLP-1/glucagon agonist design through 2041. This extensive IP coverage underpins long-term revenue potential and deters competing obesity therapies.
2. Promising Phase 1b Weight Loss Data
In recent clinical results, participants receiving a 48 mg dose of DA-1726 achieved an average weight reduction of 9%, coupled with significant declines in waist circumference and improved glycemic control, demonstrating robust efficacy at early stages.
3. Stock Reaction and Outlook
Shares jumped over 10% in premarket trading following the patent announcement and positive trial outcomes, with technical indicators showing oversold RSI levels and bullish MACD signals. Analysts maintain a Buy rating, reflecting confidence in DA-1726’s commercial prospects and long-term exclusivity.